Jim Birchenough
Stock Analyst at Wells Fargo
(2.57)
# 2,257
Out of 4,761 analysts
41
Total ratings
42.86%
Success rate
19.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $1.07 | +86.92% | 2 | Dec 31, 2024 | |
| RGLS Regulus Therapeutics | Maintains: Equal-Weight | $2 → $3 | $1.31 | +129.01% | 5 | Mar 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $47.91 | +46.11% | 3 | Feb 22, 2024 | |
| MEIP MEI Pharma | Downgrades: Equal-Weight | $260 → $40 | $2.60 | +1,438.46% | 4 | Mar 25, 2022 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $14.39 | +233.56% | 3 | Feb 9, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $6 → $7 | $0.56 | +1,151.12% | 2 | Sep 22, 2021 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.42 | +9,054.93% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $1.91 | +632.98% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $35.53 | +308.11% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $109.95 | -42.70% | 5 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $31.12 | - | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 | $12.84 | +336.14% | 3 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $734 | $700.33 | +4.81% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $6.05 | +2,875.21% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $6.59 | +400.76% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.07
Upside: +86.92%
Regulus Therapeutics
Mar 13, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $1.31
Upside: +129.01%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $47.91
Upside: +46.11%
MEI Pharma
Mar 25, 2022
Downgrades: Equal-Weight
Price Target: $260 → $40
Current: $2.60
Upside: +1,438.46%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $14.39
Upside: +233.56%
Adaptimmune Therapeutics
Sep 22, 2021
Maintains: Equal-Weight
Price Target: $6 → $7
Current: $0.56
Upside: +1,151.12%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.42
Upside: +9,054.93%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $1.91
Upside: +632.98%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $35.53
Upside: +308.11%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $109.95
Upside: -42.70%
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $31.12
Upside: -
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $12.84
Upside: +336.14%
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $700.33
Upside: +4.81%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.05
Upside: +2,875.21%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $6.59
Upside: +400.76%